Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,396 JPY | +0.22% | -1.06% | -1.76% |
Sales 2024 * | 36.12B 230M | Sales 2025 * | 39.86B 254M | Capitalization | 125B 798M |
---|---|---|---|---|---|
Net income 2024 * | 1.36B 8.65M | Net income 2025 * | 3.71B 23.64M | EV / Sales 2024 * | 3.17 x |
Net cash position 2024 * | 10.81B 68.95M | Net cash position 2025 * | 12.21B 77.84M | EV / Sales 2025 * | 2.84 x |
P/E ratio 2024 * |
25.5
x | P/E ratio 2025 * |
23.6
x | Employees | 350 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.88% |
Latest transcript on Nxera Pharma Co., Ltd.
1 day | +0.22% | ||
1 week | -3.06% | ||
Current month | -4.90% | ||
1 month | -4.90% | ||
3 months | -9.94% | ||
6 months | +0.50% | ||
Current year | -1.76% |
Managers | Title | Age | Since |
---|---|---|---|
Chris Cargill
CEO | Chief Executive Officer | 40 | 17-09-19 |
Shinichi Tamura
FOU | Founder | 74 | 90-06-21 |
Director of Finance/CFO | - | 22-03-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shinichi Tamura
FOU | Founder | 74 | 90-06-21 |
Noriaki Nagai
BRD | Director/Board Member | 66 | 19-03-26 |
Rolf Soderstrom
BRD | Director/Board Member | 58 | 20-03-24 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.92% | 20 M€ | -21.82% | ||
1.17% | 14 M€ | -6.04% | ||
0.55% | 19 M€ | +8.86% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-30 | 1,396 | +0.22% | 955 200 |
24-05-29 | 1,393 | -2.86% | 496,800 |
24-05-28 | 1,434 | +0.35% | 414,800 |
24-05-27 | 1,429 | +1.06% | 465,000 |
24-05-24 | 1,414 | -1.81% | 623,300 |
Delayed Quote Japan Exchange, May 30, 2024 at 02:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.76% | 795M | |
-2.91% | 89.01B | |
-4.34% | 37.79B | |
-17.08% | 31.22B | |
+59.63% | 26.1B | |
-22.15% | 14.25B | |
-9.36% | 12.8B | |
-11.39% | 11.65B | |
+3.82% | 8.7B | |
-17.54% | 7.45B |
- Stock Market
- Equities
- 4565 Stock